CD28 and colon carcinoma: To further address whether 2-DG also prevents terminal exhaustion of T cells in the context of antitumor immunity, we stimulated ovalbumin (OVA)-specific OT-1 T cells with anti-CD3/CD28 for 2 days in vitro followed by 2-DG treatment for 24 h before transfer into mice bearing MC38 colon carcinomas expressing OVA (Supplementary Fig. 9h–l).